Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks

Diabetic retinopathy is an ocular disease caused by changes in the expression of inflammatory mediators and increased oxidative stress in the retina and is the leading cause of vision loss in diabetic patients. Currently, there is no treatment capable of reversing retinal damage, which represents a...

ver descrição completa

Detalhes bibliográficos
Autores: Díaz Paredes, Elena, Martín Loro, Francisco, Rodríguez Marín, Rocío, Gómez Jaramillo, Laura, Sánchez Fernández, Elena Matilde, Carrillo Carrión, Carolina, Arroba, Ana I.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/174576
Acesso em linha:https://hdl.handle.net/11441/174576
https://doi.org/10.3390/pharmaceutics17060791
Access Level:acceso abierto
Palavra-chave:Glycolipid
Zeolitic-imidazolate framework
Microglia
Inflammation
Immunemediated therapy
Diabetic retinopathy
id ES_63fd01e40333fdeab60f74f5e7a1068c
oai_identifier_str oai:idus.us.es:11441/174576
network_acronym_str ES
network_name_str España
repository_id_str
spelling Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate FrameworksDíaz Paredes, ElenaMartín Loro, FranciscoRodríguez Marín, RocíoGómez Jaramillo, LauraSánchez Fernández, Elena MatildeCarrillo Carrión, CarolinaArroba, Ana I.GlycolipidZeolitic-imidazolate frameworkMicrogliaInflammationImmunemediated therapyDiabetic retinopathyDiabetic retinopathy is an ocular disease caused by changes in the expression of inflammatory mediators and increased oxidative stress in the retina and is the leading cause of vision loss in diabetic patients. Currently, there is no treatment capable of reversing retinal damage, which represents a significant burden on the quality of life of patients. (1R)-1-Dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin stands outs as a prototype of the sp2-iminoglycolipids family for its beneficial neuroprotective effect against this chronic eye disease. Critical issues related to the low solubility and bioavailability of this glycolipid in biological settings are overcome by its encapsulation in a Zeolitic-Imidazolate Framework (ZIF) structure, resulting in homogeneous and biocompatible GlycoZIF nanoparticles. Cell studies show an enhanced cellular uptake compared with the free glycolipid, and importantly, its bioactivity is preserved once released inside cells. Methods: Extensive in vitro and ex vivo assays with diabetic retinopathy models unveil the mechanistic pathways of the designed GlycoZIF. Results: A reduction in proinflammatory mediators, increased heme oxygenase-1 level, inhibition of NLRP3 inflammasome, and reduced reactive gliosis is shown. Conclusions: These findings demonstrate for the first time the potential of Glyco-modified ZIFs for the treatment of diabetes-related ocular problems by controlling the immune-mediated inflammatory response.Multidisciplinary Digital Publishing Institute (MDPI)Química OrgánicaMinisterio de Ciencia, Innovación y Universidades (MICIU). EspañaInstituto de Salud Carlos III2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/174576https://doi.org/10.3390/pharmaceutics17060791reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésPharmaceutics, 17 (6), 791.PID2022-141034OB-C22PID2022-141034OB-C21PI22/01718https://doi.org/10.3390/pharmaceutics17060791info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1745762026-06-17T12:51:07Z
dc.title.none.fl_str_mv Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
title Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
spellingShingle Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
Díaz Paredes, Elena
Glycolipid
Zeolitic-imidazolate framework
Microglia
Inflammation
Immunemediated therapy
Diabetic retinopathy
title_short Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
title_full Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
title_fullStr Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
title_full_unstemmed Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
title_sort Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks
dc.creator.none.fl_str_mv Díaz Paredes, Elena
Martín Loro, Francisco
Rodríguez Marín, Rocío
Gómez Jaramillo, Laura
Sánchez Fernández, Elena Matilde
Carrillo Carrión, Carolina
Arroba, Ana I.
author Díaz Paredes, Elena
author_facet Díaz Paredes, Elena
Martín Loro, Francisco
Rodríguez Marín, Rocío
Gómez Jaramillo, Laura
Sánchez Fernández, Elena Matilde
Carrillo Carrión, Carolina
Arroba, Ana I.
author_role author
author2 Martín Loro, Francisco
Rodríguez Marín, Rocío
Gómez Jaramillo, Laura
Sánchez Fernández, Elena Matilde
Carrillo Carrión, Carolina
Arroba, Ana I.
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Química Orgánica
Ministerio de Ciencia, Innovación y Universidades (MICIU). España
Instituto de Salud Carlos III
dc.subject.none.fl_str_mv Glycolipid
Zeolitic-imidazolate framework
Microglia
Inflammation
Immunemediated therapy
Diabetic retinopathy
topic Glycolipid
Zeolitic-imidazolate framework
Microglia
Inflammation
Immunemediated therapy
Diabetic retinopathy
description Diabetic retinopathy is an ocular disease caused by changes in the expression of inflammatory mediators and increased oxidative stress in the retina and is the leading cause of vision loss in diabetic patients. Currently, there is no treatment capable of reversing retinal damage, which represents a significant burden on the quality of life of patients. (1R)-1-Dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin stands outs as a prototype of the sp2-iminoglycolipids family for its beneficial neuroprotective effect against this chronic eye disease. Critical issues related to the low solubility and bioavailability of this glycolipid in biological settings are overcome by its encapsulation in a Zeolitic-Imidazolate Framework (ZIF) structure, resulting in homogeneous and biocompatible GlycoZIF nanoparticles. Cell studies show an enhanced cellular uptake compared with the free glycolipid, and importantly, its bioactivity is preserved once released inside cells. Methods: Extensive in vitro and ex vivo assays with diabetic retinopathy models unveil the mechanistic pathways of the designed GlycoZIF. Results: A reduction in proinflammatory mediators, increased heme oxygenase-1 level, inhibition of NLRP3 inflammasome, and reduced reactive gliosis is shown. Conclusions: These findings demonstrate for the first time the potential of Glyco-modified ZIFs for the treatment of diabetes-related ocular problems by controlling the immune-mediated inflammatory response.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/174576
https://doi.org/10.3390/pharmaceutics17060791
url https://hdl.handle.net/11441/174576
https://doi.org/10.3390/pharmaceutics17060791
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Pharmaceutics, 17 (6), 791.
PID2022-141034OB-C22
PID2022-141034OB-C21
PI22/01718
https://doi.org/10.3390/pharmaceutics17060791
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute (MDPI)
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute (MDPI)
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409613295648768
score 15.812455

Registos relacionados